Tobacco Use
Conditions
Keywords
Tobacco, Smoking, Heated tobacco
Brief summary
This is a randomized, controlled, six-way crossover clinical study to characterize the nicotine PK (pharmacokinetic) and subjective effects of HTPs (Heated Tobacco Products) comprised of 2 menthol varieties and 2 tobacco flavor varieties (Ploom® HTPs, Japan Tobacco Inc.) in adult menthol and non-menthol combustible cigarette smokers (males and females between the ages of 22 and 65). The study will include participants' UBCC (Usual Brand Combustible Cigarette) and a nicotine gum (Nicorette®) as high and low abuse liability reference products, respectively, to the HTP. Study participation is expected to last up to 34 days, including a 28-day screening period (that includes a 5-day at-home HTP product trial period), and a 6-day in-clinic confinement period (from Check-in \[Day -1\] through the end-of-study \[EOS\] visit on Day 6).
Detailed description
This is a randomized, controlled, six-way crossover clinical study to characterize the nicotine PK and subjective effects of HTPs (2 menthol varieties, Products A and B; 2 tobacco flavor varieties, Products C and D) in adult menthol and non-menthol combustible cigarette smokers. The study will include participants' UBCC (Product F) and a nicotine gum (Product E) as high and low abuse liability reference products, respectively, to the HTP. Product A: Ploom® 3.1 HTP - Menthol HTS; MX3 (681) Product B: Ploom® 3.1 HTP - Menthol HTS; MX5 (706) Product C: Ploom® 3.1 HTP - Tobacco HTS; R8 (120) Product D: Ploom® 3.1 HTP - Tobacco HTS; RX4 (953) Product E: Nicorette® 4 mg Mint Nicotine Gum Product F: Combustible Cigarette (menthol or non-menthol), participant's usual brand The study will include generally healthy adult males and females who smoke factory manufactured combustible cigarettes. This study will recruit approximately 60 participants (composed of approximately 30 menthol and 30 non-menthol adult smokers) in an attempt to obtain approximately 48 study completed participants (approximately 24 menthol and 24 non-menthol smokers). Adult participants will be between 22 and 65 years of age at screening, inclusive. Participants must have a history of smoking ≥ 10 to ≤ 30 menthol or non-menthol cigarettes daily for at least 12 months prior to screening. Enrolled participants will be randomized based on sex and their UBCC (menthol or non-menthol) to one of 6 product use sequences. Screening will occur within 28 days prior to Day 1 and includes administering the FTCD (Fagerstrom Test for Cigarette Dependence), standard safety procedures, collection of baseline information, and a 5-day at-home HTP product trial period. Enrollment visit (Day -6) will occur 5 days prior to Check-in (Day -1). Participants will receive the Ploom® HTP products for at-home product acclimation to become familiar with the product during the next 5 days. Training on how to use the Ploom® HTP device will be provided to each participant at the Enrollment visit. Participants will receive all four varieties of HTS on Day -6 and begin the at-home product trial. Participants are required to use each HTS variety at least once a day ad libitum for a minimum of 20 HTS uses over 5 days. Participants will check-in on the morning of Day -1. Product use sequence randomization and assignment will also occur on Day -1. Participants will be randomized based on sex and their UBCC (menthol or non-menthol) to one of six product use sequences. Once participants are randomized to a product use sequence, product use sessions in confinement will start. Participants will remain in confinement at the clinic until completion of all study activities on Day 6. Starting on Day -1 (following Check-in) through Day 5, depending on the randomized product use sequence, participants will use their assigned product (HTP, UBCC, or nicotine gum) during an afternoon product use session. Participants will use the same assigned product to be tested during the next day's morning ad libitum product use PK test session (e.g., if a participant is assigned to Product A \[HTP\] as the product to be used in the morning ad libitum product use PK test session on Day 1, the participant will use Product A \[HTP\] during the afternoon product use session on Day -1). The afternoon product use session should be no more than approximately 6 hours long. Participants will be required to use the assigned study product at least once, but no more than six HTS, UBCC, or nicotine gum ad libitum per daily afternoon product use sessions. Participants will then be required to abstain from any tobacco- or nicotine-containing products for at least 12 hours prior to the start of the following morning's ad libitum product use PK test session. Morning ad libitum product use PK test sessions will occur on the mornings of Days 1, 2, 3, 4, 5, and 6 (for a total of 6 morning ad libitum product use PK test sessions). During the morning ad libitum product use PK test session, participants will use the assigned study product per their assigned product use sequence. Participants will use a single UBCC or HTP for 5 minutes ad libitum or use the nicotine gum for 30 minutes per product use instruction. Blood samples for PK will be collected prior to and for 3 hours following the start of each morning ad libitum product use PK test session. Heart rate measurements will be taken at specified time points during each morning ad libitum product use PK test session. In addition, participants will complete subjective effects questionnaires (Product Liking, Tobacco/Nicotine Withdrawal, Direct Effects of Product, Use Product Again, and mCEQ) at designated time points during each morning ad libitum product use PK test session. Participants will remain in confinement starting with Check-in on Day -1 until discharge after all study activities are completed on Day 6. Participants will not be forced to use the tobacco/nicotine products at any time during the study.
Interventions
OTHERProduct A
Use of Product A in controlled use and ad libitum use sessions
OTHERProduct B
Use of Product B in controlled use and ad libitum use sessions
OTHERProduct C
Use of Product C in controlled use and ad libitum use sessions
OTHERProduct D
Use of Product D in controlled use and ad libitum use sessions
OTHERProduct E
Use of Product E in controlled use and ad libitum use sessions
OTHERProduct F
Use of Product F in controlled use and ad libitum use sessions
Sponsors
Altria Client Services LLC
Celerion
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)
Masking description
Study participants will know when they are using their UBCC (usual brand combustible cigarette) and the nicotine gum. However, participants will not be informed of which Ploom® HTS (heated tobacco stick) product they are using. Participants will not see the stick or device packaging.
Intervention model description
A randomized, controlled, six-way crossover clinical study to characterize the nicotine PK and subjective effects of HTPs (2 menthols, Products A and B; 2 tobacco flavors, Products C and D). Reference products include participants' UBCC (Product F) and nicotine gum (Product E). On Day -1 participants who completed the at-home study product trial and meet all inclusion/ exclusion criteria to be randomized at 1:1:1:1:1:1 ratio into 1 of 6 sequences in a 6x6 Latin Square Design as listed below: Sequence 1 = ABFCED; Sequence 2 = BCADFE; Sequence 3 = CDBEAF; Sequence 4 = DECFBA; Sequence 5 = EFDACB; Sequence 6 = FAEBDC. Product A: Ploom® 3.1 HTP - Menthol HTS; MX3 (681); Product B: Ploom® 3.1 HTP - Menthol HTS; MX5 (706); Product C: Ploom® 3.1 HTP - Tobacco HTS; R8 (120); Product D: Ploom® 3.1 HTP - Tobacco HTS; RX4 (953); Product E: Nicorette® 4 mg Mint Nicotine Gum; Product F: Combustible Cigarette (menthol or non-menthol), participant's usual brand
Eligibility
Sex/Gender
ALL
Age
22 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Participants must be informed of the nature and risks of the study and voluntarily give written informed consent prior to screening. 2. Healthy adult males and females ≥ 22 and ≤ 65 years of age, inclusive, at screening. 3. Participants must self-report currently smoking menthol or non-menthol factory manufactured combustible cigarettes. Participants will have a history of smoking ≥ 10 to ≤ 30 menthol or non-menthol factory manufactured combustible cigarettes daily for at least 12 months prior to screening. Prior to screening, brief periods (i.e., up to 7 consecutive days) of non-smoking within 90 days before Check-in (e.g., due to illness or participation in a clinical study where tobacco use was prohibited) will not be exclusionary at the discretion of the Investigator (other non-daily tobacco use, except for heated tobacco use, within 30 days prior to screening are not exclusionary). 4. Participants must be generally healthy, free of lifetime malignant tumors, and without clinically significant abnormalities as assessed by the Investigator based on the review of medical and surgical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluations conducted at screening and Check-in, as applicable (refer to Table 1). A single repeat measurement/test may be performed to confirm vital signs, 12-lead ECG, and clinical laboratory tests abnormalities (i.e., to confirm that a participant is eligible). 5. Screening and Check-in systolic/diastolic blood pressure ≤ 150/90 mmHg measured after being seated quietly for at least 10 minutes. Two rechecks may be performed at the Investigator's discretion. 6. Urine cotinine ≥ 500 ng/mL at screening. 7. Exhaled carbon monoxide ≥ 10 ppm at screening. 8. Negative pregnancy test at screening and Check-in (Day -1) for all female participants. 9. Female participants who are sexually active and of childbearing potential (i.e., not surgically sterile at least 6 months prior to Check-in nor post-menopausal with amenorrhea for at least 1 year prior to Check-in and FSH levels consistent with postmenopausal status) must not be lactating and must have been using one of the following forms of contraception from 3 months before first study product administration through 30 days after the final administration of study product: * hormonal (e.g., oral, vaginal ring, transdermal patch, implant, injection) consistently for at least 3 months prior to Check-in, when used in combination with male condoms with spermicide (use of NuvaRing® is at the Investigator's discretion) * double barrier (e.g., condom with spermicide or diaphragm with spermicide) consistently for at least 2 weeks prior to Check-in * intrauterine device or system (utilize Investigator discretion regarding use of hormonal or nonhormonal devices) for at least 3 months prior to Check-in * exclusive partner who is clinically sterile (i.e., documented infertility or surgical sterilization; see below for additional information on sterility) or has been vasectomized for at least 6 months (inclusive) prior to Check-in Note: Sexual abstinence, defined as refraining from intercourse, is allowed when this is in line with the preferred and usual lifestyle of the participant. Female participants of childbearing potential who are not currently engaging in heterosexual intercourse must agree to use one of the above methods of birth control through completion of study, in the event that they have heterosexual intercourse during the course of the study. 10. Female participants who are of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to Check-in: * hysteroscopic sterilization with documentation of success with hysterosalpingogram * bilateral tubal ligation or bilateral salpingectomy * hysterectomy * bilateral oophorectomy * Essure® or be post-menopausal with amenorrhea for at least 1 year prior to Check-in and confirmed by FSH levels consistent with post-menopausal status. 11. Able to communicate effectively with the study personnel and willing to comply with the requirements of the study. 12. Willing and able to use all of the study products. This includes product use during the at-home product trial and the in-confinement product use sessions. If participants are unwilling to use or unable to tolerate any of the study products they will not participate in this study.
Exclusion criteria
1. Use of any HTPs within the past 30 days prior to the screening visit; occasional use (i.e., not daily use) of other types of tobacco- or nicotine-containing products other than factory manufactured combustible cigarettes (e.g., roll-your-own cigarettes, e-cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) are allowed within the past 30 days prior to screening. 2. Any postponement of a quit attempt to participate in the study; or any attempts to quit smoking in the 3 months prior to Day -1 (Check-in). 3. Self-reported puffers (i.e., smokers who draw smoke from the combustible cigarette into the mouth and throat but do not inhale). 4. Poor dentition that prevents participant from using nicotine gum. 5. History or presence of any type of malignant tumor or clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would interfere with the absorption, distribution, metabolism, or excretion of cotinine or jeopardize the safety of the participant or impact the validity of the study results. 6. Current evidence or any history of congestive heart failure. 7. Any other condition or prior therapy that, in the Investigator's opinion, would make the participant unsuitable for the study, or unable or unwilling to comply with the study procedures. 8. Clinically significant abnormal vital sign, physical examination (including oral cavity an oropharynx), medical history, or clinical laboratory finding(s), in the opinion of the Investigator. 9. Positive test for human immunodeficiency virus (HIV)-1 or HIV-2; or hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) consistent with current infection at screening. 10. Diabetes mellitus that is not controlled by diet/exercise alone, in the opinion of the Investigator. Fasting plasma glucose \> 126 mg/dL (7 mmol/L) is exclusionary. One recheck may be performed for fasting plasma glucose values \> 126 mg/dL but \< 200 mg/dL. 11. An acute illness (e.g., upper respiratory infection, viral infection) requiring treatment with prescribed medicines within 2 weeks prior to Check-in. 12. History of surgery or major trauma within 12 weeks of screening, or surgery planned during the study through EOS. 13. History of alcohol abuse or drug abuse within 24 months prior to Check-in. 14. Consumption of alcohol-containing food or beverages within 48 hours prior to Check-in. 15. Positive screen for alcohol (breath or urine) or any of the following drugs of abuse (urine), regardless of the reason of use: amphetamines, methamphetamines, opiates, cannabinoids, or cocaine at screening or Check-in. 16. Fever (i.e., body temperature \> 100.5°F) at screening or Check-in; 1 recheck may be performed at the Investigator's discretion. 17. Body mass index (NHLBI) \> 40.0 kg/m2 or \< 18.0 kg/m2 at screening. 18. Estimated glomerular filtration rate \< 80 mL/minute using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (Medscape) at screening. 19. Serum alanine aminotransferase ≥ 1.5 times the upper limit of normal and/or aspartate aminotransferase ≥ 2.0 times the upper limit of normal at screening; 1 recheck may be performed at the Investigator's discretion. 20. Female participants who are pregnant (positive pregnancy test at screening or Check-in), lactating, or intend to become pregnant from screening through EOS. 21. Use of prescription or over-the-counter (OTC) bronchodilator medication (e.g., inhaled or oral β-agonists) for treatment of any illness within 12 months prior to Check-in. 22. Use of antibiotics within 2 weeks prior to Check-in. Also refer to Section 5.7.1. 23. Use of medications known or are suspected to interact with cytochrome P450 2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram, entacapone, fenofibrate, isoniazid, ketoconazole, letrozole, methimazole, methoxsalen, metyrapone, miconazole, modafinil, orphenadrine, pentobarbital, phenobarbital, pilocarpine, primidone, propoxyphene, quinidine, rifampicin, rifampin, secobarbital, selegiline, sulconazole, tioconazole, tranylcypromine) within 14 days or 5 half-lives of the drug, whichever is longer, prior to Check-in. 24. Has taken other investigational drugs/products or participated in any clinical study for an investigational drug, device, biologic, or for a tobacco product within 30 days or 5 halflives (if known) of the investigational product's PK, pharmacodynamic, or biological activity (if known), whichever is longer, prior to first administration of study product in this study or is currently participating in another clinical study; or participation in \> 2 ALCS-sponsored studies within the past 12 month period prior to Check-in. 25. Has received a vaccination within 14 days prior to Check-in. 26. Plasma donation within 7 days prior to Day 1. 27. Donation of ≥ 1 unit of blood or blood products (with the exception of plasma as noted), had significant blood loss \> 450 mL, or received whole blood or a blood product transfusion within 56 days prior to Day -1. 28. Strenuous activity (as assessed by the Investigator) within 48 hours prior to Check-in. 29. Participant or a first-degree relative (i.e., parent, sibling, child, spouse) is a current or former employee of the tobacco industry or a named party or class representative in litigation with any tobacco company. 30. Participant or a first-degree relative (i.e., parent, sibling, child, spouse) is a current employee of the study site. 31. Unwilling or unlikely to comply with the requirements of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameters [Cmax] Assessment | from time zero (defined as the start of product use) to 180 minutes post-use on each Day 1 through Day 6 | Characterize PK parameters of nicotine in plasma during and after a single ad libitum use of HTP (two menthol and two tobacco flavor varieties) test products relative to UBCC and the nicotine gum reference products. Cmax: Maximum measured plasma concentration over the duration of the measurement interval from time zero (defined as the start of product use) to 180 minutes post-use on each Study Day 1 through Day 6. |
| Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameter [AUC(0-180)] Assessment | from time zero (defined as the start of product use) to 180 minutes post-use on each Study Day 1 through Day 6 | Characterize PK parameters of nicotine in plasma during and after a single ad libitum use of HTP (two menthol and two tobacco flavor varieties) test products relative to UBCC and the nicotine gum reference products. AUC(0-180): Area under the nicotine concentration-time curve calculated using linear trapezoidal summation from time zero (defined as the start of product use) to 180 minutes post-use on each Study Day 1 through Day 6. |
| Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameter [Tmax] Assessment | Day 1 through Day 6 | Characterize PK parameters of nicotine in plasma during and after a single ad libitum use of HTP (two menthol and two tobacco flavor varieties) test products relative to UBCC and the nicotine gum reference products. Tmax: Time of the maximum measured plasma concentration over the duration of the measurement interval. |
Countries
United States
Participant flow
Pre-assignment details
80 participants enrolled in the Product Trial period and 20 participants were dropped out prior to study randomization on Day -1, resulting in 60 participants randomized into study.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 41.5 years STANDARD_DEVIATION 5.8 |
| BMI | 32.500 kg/m² STANDARD_DEVIATION 6.2307 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 59 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Height | 171.4 cm STANDARD_DEVIATION 10.09 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 22 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 36 Participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 5 Participants |
| Weight | 101.07 kg STANDARD_DEVIATION 20.555 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 80 | 0 / 58 | 0 / 58 | 0 / 60 | 0 / 59 | 0 / 57 | 0 / 57 |
| other Total, other adverse events | 2 / 80 | 1 / 58 | 3 / 58 | 2 / 60 | 1 / 59 | 8 / 57 | 1 / 57 |
| serious Total, serious adverse events | 0 / 80 | 0 / 58 | 0 / 58 | 0 / 60 | 0 / 59 | 0 / 57 | 0 / 57 |
Outcome results
None listed